Relovair Bet Fuels Glaxo's $213M Theravance Stake Buy
The announcement comes 10 days after the firms disclosed mixed results in clinical trials of Relovair. The drug is seen as a possible successor to highly profitable Advair, which no longer has U.S. patent protection.
In a statement, GSK said it’s acquiring 10 million shares of Theravance common stock for...
To view the full article, register now.